Panic Disorder (PD) is a debilitating anxiety condition defined by recurrent, unexpected panic attacks—abrupt surges of intense fear or discomfort that peak within minutes. The disorder is not merely about the attacks themselves; it requires at least one month of persistent anticipatory anxiety (worrying about future attacks) or significant maladaptive behavioural changes (avoiding exercise, social situations, or places where escape might be hard) following an attack. PD affects 2-3% of the population annually, typically emerges in late adolescence or early adulthood, and is twice as common in women as in men. A notable 95% of individuals with agoraphobia also have a comorbid diagnosis of panic disorder.
Neurobiological Underpinnings
- Prevalence: Affects 2-3% of adults annually; lifetime prevalence ~4.7%
- Age of Onset: Median onset 20-24 years; onset after 45 is rare
- Genetic Risk: First-degree relatives have a 4-7 times greater chance of developing PD
- Key Brain Regions: Dorsomedial hypothalamus (DMH) and amygdala show altered GABA-A and serotonin receptor binding
- Biomarkers: Elevated Interleukin 6 (IL-6) and leptin suggest stress-induced inflammatory changes
Clinical Manifestations (DSM-5-TR Criteria)
A panic attack requires ≥4 of 13 symptoms peaking within 10 minutes :
- Cardiorespiratory: Palpitations, chest pain, shortness of breath, choking sensation
- Autonomic: Sweating, trembling, chills or hot flashes
- Gastrointestinal: Nausea, abdominal distress
- Neurological: Dizziness, paresthesias (numbness/tingling)
- Cognitive: Fear of dying, fear of losing control, derealization, depersonalization
Nocturnal panic attacks—waking from sleep in a state of terror—are a hallmark of PD, occurring when no external trigger is present.
First-Line Treatments
Pharmacotherapy :
- SSRIs (First-Line): Sertraline (start 25mg for panic sensitivity), Escitalopram (10mg), Paroxetine
- Critical Note: Start at half the usual dose due to hypersensitivity to side effects
- SNRIs: Venlafaxine XR (37.5-75mg), Duloxetine
- Benzodiazepines: Alprazolam (0.25-0.5mg), Clonazepam (0.25mg BID)—effective acutely but not first-line due to dependence risk (use short-term, 2-4 weeks max)
- TCAs: Imipramine, Clomipramine—effective but reserved for non-responders due to side effect profile
Psychotherapy :
- Cognitive Behavioural Therapy (CBT): Response rate 38% (Number Needed to Treat = 5.0)
- Interoceptive Exposure: Simulates somatic sensations (dizziness, racing heart) to break the fear-of-fear cycle; improves clinical effects by >40%
- Inhibitory Learning: Teaches patients to tolerate anxiety rather than eliminate it immediately
- Digital CBT (dCBT): Effect size g=0.70 vs. passive controls; efficacy comparable to face-to-face therapy
Without treatment, PD follows a chronic, waxing and waning course. Some individuals have frequent attacks; others experience episodic symptoms with periods of remission. Suicidal ideation and attempts occur at higher rates, even independent of comorbid depression. However, with appropriate treatment—combining SSRIs and CBT—most patients achieve significant symptom reduction, reclaiming autonomy from the tyrannical grip of recurrent panic and anticipatory dread.
